Company news
Krystal Biotech, Inc. (NASDAQ:KRYS) news
Krystal Biotech, Inc. news releases on 6ix. Latest, Sep 13, 2024: Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference
Press releases — page 2
Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference
September 12, 2024
Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 5, 2024
Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté
August 27, 2024
Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates
August 4, 2024
Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024
July 25, 2024
Krystal Biotech to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 4, 2024
Krystal Biotech to Present at the American Thoracic Society 2024 International Conference
May 14, 2024
Krystal Biotech to Present at BofA Securities 2024 Health Care Conference
May 7, 2024
Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates
May 5, 2024
Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
May 1, 2024
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
April 25, 2024
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
April 21, 2024
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
April 3, 2024
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference
February 27, 2024
Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
February 25, 2024
Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
February 19, 2024
Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung
February 12, 2024
Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa
February 7, 2024
Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference
January 31, 2024
Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®
January 3, 2024
Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)
December 18, 2023
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
November 26, 2023
Krystal Biotech to Present at the Stifel 2023 Healthcare Conference
November 8, 2023
Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update
November 5, 2023
Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023
October 29, 2023
Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference
September 27, 2023
Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency
September 20, 2023
Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 6, 2023
Krystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
September 4, 2023
Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million
August 20, 2023
Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights
August 6, 2023
Krystal Biotech Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707
July 25, 2023
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis
July 2, 2023
Krystal Biotech to Present at Upcoming Investor Conferences
June 4, 2023
Krystal Biotech Announces $160 Million Private Placement Equity Financing
May 21, 2023
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa
May 18, 2023
Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights
May 7, 2023
Krystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use Program
April 23, 2023
Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest
April 17, 2023
Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual Meeting
April 12, 2023
Krystal Biotech Appoints Catherine Mazzacco to Board of Directors
March 5, 2023
Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference
March 1, 2023
Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
February 26, 2023
Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
January 17, 2023
Krystal Biotech Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa
January 8, 2023
New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa
December 13, 2022
Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference
December 4, 2022
Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference
November 30, 2022
Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022
Jeune Aesthetics Announces Positive Durability Results for KB301 in the PEARL-1 Extension Cohort, an Investigational Gene-based Treatment for Improvement of Fine Lines and Wrinkles
November 16, 2022